Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDURANCE: VRd vs CRd in Newly Diagnosed Multiple Myeloma
NCT01863550Phase 3Active, not recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Dec 2013
- Primary completion
- Dec 2026
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 2
01
Overview
A Phase 3 trial of carfilzomib, bortezomib in multiple myeloma (MM), sponsored by ECOG-ACRIN Cancer Research Group. Started Dec 2013; status: active, not recruiting.
02
Drugs
carfilzomibbortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01863550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01863550.